Facile preparation of biocompatible Ti2O3 nanoparticles for second near-infrared window photothermal therapy. Issue 47 (14th November 2018)

• Record Type: Journal Article
• Authors: Zeng, Jinhua; Wu, Ming; Lan, Shanyou; Li, Jiong; Zhang, Xiaolong; Liu, Jingfeng; Liu, Xiaolong; Wei, Zuwu; Zeng, Yongyi
• Is Part Of: Journal of materials chemistry. Volume 6:Issue 47(2018)
• Page Start: 7889
• Page End: 7897
• Publication Date: 2018-11-14
• Subjects: Materials -- Periodicals; Chemistry, Analytic -- Periodicals; Biomedical materials -- Research -- Periodicals; 543.0284
• DOI: 10.1039/c8tb02079e
• Languages: English
• ISSNs: 2050-750X

Abstract

Abstract : NIR-II photothermal therapy (PTT) agents of Ti2 O3 nanoparticles have been developed. Abstract : Photothermal therapy (PTT) is emerging as a powerful tool for the treatment of cancer. However, typical photothermal agents are excited by conventional near-infrared light (NIR-I, 700–900 nm), which leads to low tissue penetration and significantly hinders their further application. Compared with NIR-I light, the second NIR optical window light (NIR-II, 1000–1700 nm) can remarkably increase the tissue penetration depth; however, photothermal agents in this optical window are extremely limited and need to be further explored. Herein, we prepared Ti2 O3 nanoparticles through a ball milling method, and to further improve their biocompatibility and targeting efficiency, the Ti2 O3 nanoparticles were modified with hyaluronic acid. The as-prepared nanoparticles exhibited strong light absorption and excellent photothermal conversion efficiency in the NIR-II optical window. Both in vitro and in vivo studies clearly demonstrated that the Ti2 O3 @HA nanoparticles not only exhibit high biocompatibility and photostability, but also can be efficiently taken up by cancer cells and display excellent anticancer ability in the NIR-II region. Thus, this study provides a novel photothermal agent for PTT in the NIR-II optical window, which may further advance cancer photo-treatment in future.